Insight into the cancer cell populations that are responsible for relapsed disease is needed to improve outcomes. Here we report a single-cell-based study of B cell precursor acute lymphoblastic leukemia at diagnosis that reveals hidden developmentally dependent cell signaling states that are uniquely associated with relapse. By using mass cytometry we simultaneously quantified 35 proteins involved in B cell development in 60 primary diagnostic samples. Each leukemia cell was then matched to its nearest healthy B cell population by a developmental classifier that operated at the single-cell level. Machine learning identified six features of expanded leukemic populations that were sufficient to predict patient relapse at diagnosis. These features implicated the pro-BII subpopulation of B cells with activated mTOR signaling, and the pre-BI subpopulation of B cells with activated and unresponsive pre-B cell receptor signaling, to be associated with relapse. This model, termed 'developmentally dependent predictor of relapse' (DDPR), significantly improves currently established risk stratification methods. DDPR features exist at diagnosis and persist at relapse. By leveraging a data-driven approach, we demonstrate the predictive value of single-cell 'omics' for patient stratification in a translational setting and provide a framework for its application to human cancer.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukemia. Nature 469, 356–361 (2011).
Walter, M.J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090–1098 (2012).
Welch, J.S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
Klco, J.M. et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379–392 (2014).
Duque-Afonso, J. & Cleary, M.L. The AML salad bowl. Cancer Cell 25, 265–267 (2014).
Bhojwani, D. & Pui, C.H. Relapsed childhood acute lymphoblastic leukemia. Lancet Oncol. 14, e205–e217 (2013).
Greaves, M.F. Differentiation-linked leukemogenesis in lymphocytes. Science 234, 697–704 (1986).
Bhojwani, D. et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 108, 711–717 (2006).
Mullighan, C.G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377–1380 (2008).
Hogan, L.E. et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 118, 5218–5226 (2011).
Mullighan, C.G. et al. BCR–ABL1 lymphoblastic leukemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008).
LeBien, T.W. & Tedder, T.F. B lymphocytes: how they develop and function. Blood 112, 1570–1580 (2008).
Bendall, S.C. et al. Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development. Cell 157, 714–725 (2014).
Teachey, D.T. & Hunger, S.P. Predicting relapse risk in childhood acute lymphoblastic leukemia. Br. J. Haematol. 162, 606–620 (2013).
Spitzer, M.H. et al. An interactive reference framework for modeling a dynamic immune system. Science 349, 1259425 (2015).
Samusik, N., Good, Z., Spitzer, M.H., Davis, K.L. & Nolan, G.P. Automated mapping of phenotype space with single-cell data. Nat. Methods 13, 493–496 (2016).
Zunder, E.R., Lujan, E., Goltsev, Y., Wernig, M. & Nolan, G.P. A continuous molecular roadmap to iPSC reprogramming through progression analysis of single-cell mass cytometry. Cell. Stem Cell 16, 323–337 (2015).
Bicocca, V.T. et al. Cross-talk between ROR1 and the pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 22, 656–667 (2012).
Crist, W. et al. Prognostic importance of the pre-B cell immunophenotype and other presenting features in B lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 74, 1252–1259 (1989).
Mullighan, C.G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia. Nature 446, 758–764 (2007).
Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).
Tibshirani, R. The lasso method for variable selection in the Cox model. Stat. Med. 16, 385–395 (1997).
Tibshirani, R.J. & Efron, B. Pre-validation and inference in microarrays. Stat. Appl. Genet. Mol. Biol. 1, Article1 (2002).
Höfling, H. & Tibshirani, R. A study of pre-validation. Ann. Appl. Stat. 2, 643–664 (2008).
Uno, H., Cai, T., Tian, L. & Wei, L.J. Evaluating prediction rules for t-year survivors with censored regression models. J. Am. Stat. Assoc. 102, 527–537 (2007).
Uno, H., Cai, T., Pencina, M.J., D'Agostino, R.B. & Wei, L.J. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Statist. Med. 121, 1105–1117 (2011).
Smith, M. et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J. Clin. Oncol. 14, 18–24 (1996).
Basso, G. et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J. Clin. Oncol. 27, 5168–5174 (2009).
Borowitz, M.J. et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111, 5477–5485 (2008).
Pencina, M.J., D'Agostino, R.B. Sr. & Steyerberg, E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat. Med. 30, 11–21 (2011).
Uno, H., Tian, L., Cai, T., Kohane, I.S. & Wei, L.J. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat. Med. 32, 2430–2442 (2013).
Krishnaswamy, S. et al. Conditional density-based analysis of T cell signaling in single-cell data. Science 346, 1250689 (2014).
Clark, M.R., Mandal, M., Ochiai, K. & Singh, H. Orchestrating B cell lymphopoiesis through interplay of IL7 receptor and preB cell receptor signaling. Nat. Rev. Immunol. 14, 69–80 (2014).
O'Reilly, L.A. et al. MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation. J. Immunol. 183, 261–269 (2009).
Alizadeh, A.A. et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
Trageser, D. et al. Pre-B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requires IKAROS function. J. Exp. Med. 206, 1739–1753 (2009).
Feldhahn, N. et al. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J. Exp. Med. 201, 1837–1852 (2005).
Shojaee, S. et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat. Med. 22, 379–387 (2016).
Kotecha, N. et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14, 335–343 (2008).
Gibbs, K.D. Jr. et al. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell. Stem Cell 10, 210–217 (2012).
Irish, J.M. et al. B cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc. Natl. Acad. Sci. USA 107, 12747–12754 (2010).
Irish, J.M. et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118, 217–228 (2004).
Levine, J.H. et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184–197 (2015).
Conter, V. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B cell precursor acute lymphoblastic leukemia: results in 3,184 patients of the AIEOP-BFM ALL 2000 study. Blood 115, 3206–3214 (2010).
WHO Expert Committee. Acute lymphoblastic leukemia in children: a brief review of the internationally available protocols. (Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines) 1–11 (World Health Organization, Geneva, 2008).
Bendall, S.C. et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332, 687–696 (2011).
Fienberg, H.G., Simonds, E.F., Fantl, W.J., Nolan, G.P. & Bodenmiller, B. A platinum-based covalent viability reagent for single-cell mass cytometry. Cytometry A 81, 467–475 (2012).
Zunder, E.R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10, 316–333 (2015).
Finck, R. et al. Normalization of mass cytometry data with bead standards. Cytometry A 83, 483–494 (2013).
We thank G. Fragiadakis, M.H. Spitzer, P.F. Gherardini, A. Tsai, R.M. Angelo, J. Levine, M. O'Brien, D. Pe'er, M. Shipp and members of the ASH–EHA TRTH program for discussions. This work received funding from the Stanford Immunology NIH Training Program (grant no. 5T32AI007290-29, 5T32AI007290-30, 5T32AI007290-32 and 2T32AI007290-31; all to Z.G.), the Fondazione Italiana per la Ricerca sul Cancro (FIRC-AIRC; grant no. 19488; J.S.), the M. Tettamanti Foundation and Benedetta è la vita ONLUS Foundation (J.S.), a Damon Runyon Cancer Research Foundation Fellowship (DRG-2017-09; S.C.B.), the US National Institutes of Health (NIH) (grant no. K99GM104148-01; S.C.B.) and the Associazione Italiana per la Ricerca sul Cancro (grant no. 20564; A.B.). G.P.N. is supported by NIH grants R01CA184968, 1R01GM10983601, 1R01NS08953301, 1R01CA19665701, R01HL120724, 1R21CA183660, R33CA0183692, 1R33CA183654-01, U19AI057229, 1U19AI100627, U54-UCA149145A, N01-HV-00242 HHSN26820100034C and 5UH2AR067676, NIH Northrop–Grumman Corporation subcontract 7500108142, US Food and Drug Administration (FDA) grants HHSF223201210194C and BAA-15-00121, US Department of Defense (DOD) grants OC110674 and W81XWH-14-1-0180, the NWCRA Entertainment Industry Foundation, and the Bill and Melinda Gates Foundation grant OPP1113682. K.L.D. is supported by the NetApp St. Baldrick's Foundation Scholar award and a CureSearch Young Investigator award. Z.G. and G.P.N. are members of the Parker Institute for Cancer Immunotherapy, which supported the Stanford Cancer Immunotherapy Program.
S.C.B. and G.P.N. are paid consultants for Fluidigm, the manufacturer that produced some of the reagents and instrumentation used in this study.
About this article
Cite this article
Good, Z., Sarno, J., Jager, A. et al. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nat Med 24, 474–483 (2018). https://doi.org/10.1038/nm.4505
Scientific Reports (2021)
Nature Communications (2021)
Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia
Frontiers of Medicine (2021)
Current Oncology Reports (2021)
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia
Nature Cancer (2021)